Basic information
- CAS
302-79-4- Standard SMILES
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1- InChIKey
SHGAZHPCJJPHSC-YCNIQYBTSA-N- Molecular formula
- C20H28O2
- Average molar mass
- 300.4 g/mol
- Monoisotopic mass
- 300.20893013
Names & identifiers
- Preferred name
- Retinoic Acid
- IUPAC
- (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
- English name
- Retinoic acid
- Molecular formula
- C20H28O2
- Molecular weight
- 300.44
Names & synonyms
Show more names
Database identifiers
- CAS
302-79-4、97950-17-9- PubChem CID
- 444795
- DTXSID
DTXSID7021239- ChEMBL
CHEMBL38- ChEBI
CHEBI:15367- UNII
- 5688UTC01R
- EC Number
- 206-129-0
- Nikkaji
- J1.313.469C、J1.518K、J2.378.058E、J494.243D、J690.379G、J970.183D
Properties
Computed structural properties
- XLogP
- 6.3
- Topological polar surface area
- 37.3 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 2
- Rotatable bonds
- 5
- Heavy atoms
- 22
- Formal charge
- 0
- Complexity
- 567
Physicochemical properties
- Melting point
- 180 · 180-181 °C (lit.)
- Boiling point
- 381.66 °C · 381.66°C (rough estimate)
- Density
- 1.0597 · 1.0597 (rough estimate)
- refractive index
- 1.48 · 1.4800 (estimate)
- storage temp.
- -20 °C · -20°C
- solubility
- Practically insoluble in water, soluble in methylene chloride, slightly soluble in ethanol (96 per cent).
- pka
- 4.73 · 4.73±0.33(Predicted)
- form
- powder
- color
- yellow
- biological source
- synthetic (organic)
- Water Solubility
- insoluble
- Sensitive
- Light Sensitive
- Merck
- 14 · 14,8165
- BRN
- 2057223 · 2057223
- Stability
- -20 °C · Store Dry in Freezer at -20°C for up to 1 year; in Solution at -20°C for up to 3 Months.
- InChI
- 1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
- InChIKey
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N
- SMILES
- CC1=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)(C)CCC1
- LogP
- 6.3 · 6.300
- Toxicology and Carcinogenesis
- Photococarcinogenesis Study of Retinoic Acid and Retinyl Palmitate (All-trans-retinoic acid (CASRN 302-79-4) and All-trans-retinyl palmitate (CASRN 79-81-2)) in SKH-1 Mice (Simulated Solar Light and Topical Application Study)
- CAS DataBase Reference
- 302 · 302-79-4(CAS DataBase Reference)
- EWG's Food Scores
- 5 · 5-8
- NCI Dictionary of Cancer Terms
- all-trans retinoic acid; ATRA; retina; Retin-A; retinoic acid; tretinoin; vitamin A acid
- FDA UNII
- 5688 UTC01R · 5688UTC01R
- NCI Drug Dictionary
- Aberel
- ATC code
- 10 AD01,D10AD51,L01XF01 · D10AD01,D10AD51,L01XF01
- Proposition 65 List
- All-trans Retinoic Acid
- EPA Substance Registry System
- Retinoic acid (302-79-4)
- UNSPSC Code
- 41116107 · 41116107
- NACRES
- 77 · NA.77
- Protein binding
- 95 % · >95%
- Excreted unchanged in urine
- 60 · 60 (excreted as metabolites)
- Biological half-life
- 0.5 · 0.5-2 / -
- Symbol(GHS)
- 7 · GHS07,GHS08,GHS09
- Signal word
- Danger
- Hazard statements
- 302 · H302-H315-H360FD-H410
- Precautionary statements
- 202 · P202-P264-P273-P301+P312-P302+P352-P308+P313
- PPE
- 95 · dust mask type N95 (US), Eyeshields, Gloves
- Hazard Codes
- T,Xn,N
- Risk Statements
- 22 · 22-63-38-20/21/22-51/53
- Safety Statements
- 53 · 53-26-36/37/39-45-36/37-61-24/25
- RIDADR
- 3249 · 3249
- WGK Germany
- 3 · 3
- RTECS
- 6475000 · VH6475000
- F
- 7 · 7-8-16-23
- TSCA
- TSCA listed
- HazardClass
- 6.1 · 6.1(b)
- PackingGroup
- III
- HS Code
- 29362100 · 29362100
- Storage Class
- 6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
- Hazard Classifications
- 4 OralAquatic · Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1Repr. 1BSkin Irrit. 2
- Hazardous Substances Data
- 302 · 302-79-4(Hazardous Substances Data)
- Toxicity
- 50 · LD50 (10 day) in mice, rats (mg/kg): 790, 790 i.p.; 2200, 2000 orally (Kamm)
- Limited Quantities
- 5 kg · 5.0 kg (11 lbs) (solid)
- Excepted Quantities
- Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
Safety & regulation
Safety data
- F
- 7-8-16-23
- PPE
- dust mask type N95 (US), Eyeshields, Gloves
- wgk
- 3
- tsca
- TSCA listed
- rtecs
- VH6475000
- ridadr
- 3249
- hs_code
- 29362100
- Toxicity
- LD50 (10 day) in mice, rats (mg/kg): 790, 790 i.p.; 2200, 2000 orally (Kamm)
- risk_code
- 22-63-38-20/21/22-51/53
- Signal word
- Danger
- Symbol(GHS)
- GHS07,GHS08,GHS09
- hazard_code
- T,Xn,N
- safety_code
- 53-26-36/37/39-45-36/37-61-24/25
- hazard_class
- 6.1(b)
- Storage Class
- 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
- packing_group
- III
- Hazard statements
- H302-H315-H360FD-H410
- Limited Quantities
- 5.0 kg (11 lbs) (solid)
- Excepted Quantities
- Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
- Hazard Classifications
- Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1Repr. 1BSkin Irrit. 2
- Precautionary statements
- P202-P264-P273-P301+P312-P302+P352-P308+P313
- Hazardous Substances Data
- 302-79-4(Hazardous Substances Data)
Chemistry & industry
Applications
Uses(1) Applies to abnormal tyshiyongyupe of acne, fish phosphorus disease and abnormal psoriasis. (2) Resistance to abnormal skin drugs. (3) Tretinoin mainly affects the growth of bones and epithelial metabolism, can promote epithelial cell proliferation and updates, and can inhibit the proliferation and differentiation of keratinocytes, so hyperkeratosis can be back to normal. Therefore many complete or incomplete keratosis, hyperkeratosis of diseases have a certain therapeutic effect, treat a variety of skin diseases. Tretinoin is mainly used in the treatment of psoriasis, ichthyosis, follicular keratosis, acne, lichen planus, verrucous epidermal nevus, impetigo, vitiligo, lichen psoriasis, the face of pityriasis alba, etc.
Descriptionall-trans Retinoic acid is a metabolite of vitamin A and a ligand for retinoic acid receptors (RARs) with IC50 values of 9, 3, and 10 nM for RARα, RARβ, and RARγ, respectively, in radioligand binding assays. It induces expression of a luciferase reporter in COS-7 cells expressing RARα, RARβ, or RARγ (EC50s = 169, 9, and 2 nM, respectively). all-trans Retinoic acid (17 nmol) reduces papilloma formation induced by phorbol 12-myristate 13-acetate (TPA; ) in mice. It reduces bile duct proliferation, hydroxyproline levels, and liver inflammation in a rat model of α-naphthylisothiocyanate-induced chronic cholestasis and reduces plasma levels of alkaline phosphatase and bile salts in the Mdr2-/- mouse model of cholestasis. all-trans Retinoic acid also reduces hepatic fat accumulation, triglycerides, body weight, and serum glucose levels in mice with Western diet-induced obesity.
UsesPhysiological metabolite of vitamin A. Effects gene expression via nuclear retinoic acid receptors (RAR); mediates cellular growth and differentiation
Usesretinoic acid (tretinoin) is a vitamin A derivative. It has demonstrated an ability to alter collagen synthesis, increase dermal hyaluronic acid levels, and stimulate fibroblast growth and the extracellular matrix. It is used for keratinization disorders and for treating acne. Retinoic acid’s anti-aging effect has been convincingly documented and it is often used for treating the visible signs of aging, though these results can take approximately 6 months to be visible. It is associated with a number of adverse effects, including irritation, photosensitivity, skin dryness, redness, and peeling. It should also not be used while pregnant.
General DescriptionYellow to light-orange crystalline powder.
General DescriptionTretinoin is available in 10-mg capsules for oral administrationin the treatment of APL. The mechanism of action involvespassive diffusion through the cell membrane andthen movement to the nucleus where it interacts with theretinoic acid receptor (RAR) portion of the PML-RAR fusionprotein. Binding of tretinoin allows the cell to differentiateand has also been shown to result in the destruction ofthe PML-RAR fusion protein. Resistance to tretinoin isproblematic and associated with an increase in cellularretinoic acid–binding proteins (CRAPBs) located in the cytosol.The complexation with tretinoin prevents movementinto the nucleus and may present the drug to metabolizingenzymes that inactivate it. Amino acid mutation of thePML-RAR protein has also been established as a mechanismof resistance. The agent is well absorbed upon oral administrationand highly (95%) protein bound. Metabolismoccurs in the liver and several inactive metabolites havebeen identified including 13-cis-retinoic acid, 4-oxo cisretinoic,4-oxo trans-retinoic acid and 4-oxo trans-retinoicacid glucuronide. Elimination occurs in the urine (63%) andfeces (31%) with an elimination half-life of 40 to 120 minutes.Vitamin A toxicity is seen in nearly all patients andpresents as headache, fever, dryness of the skin, skin rash,mucositis, and peripheral edema. APL differentiation syndromesuch as that seen for arsenic trioxide also occurs.Cardiovascular effects include flushing, hypotension, CHF,stroke, and myocardial infarction have been reported butoccur only rarely. There are also several CNS and GI effectsthat have been associated with the agent as well.
Upstream & downstream products
Upstream raw materials
Downstream products
Suppliers100 total
Additional notes
DefinitionChEBI: Retinoic acid is a retinoid in which all four exocyclic double bonds have E- (trans-) geometry. It is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis.
Related reactions
Compound notes
Loading…